Highlighted news indicates a range of developments for BioNTech. Singapore approved BioNTech's latest COVID-19 vaccine for all ages and another vaccine adaptation received Health Science Authority approval. Comirnaty, another product from BionTech and Pfizer, showed robust immune responses in high-risk adults. Arecent trial for a breast cancer precision drug yielded positive outcomes. The company's African mRNA vaccine production push is funded by the EU. BioNTech has plans of releasing its financial results for the third quarter of 2025. The firm also announced an R&D day set for November 11, 2025, in New York. Meanwhile, a public exchange offer for CureVac shares was advised by White & Case. The company acquired CureVac in a $1.25 billion all-stock deal, and the partnership between BMS - BioNTech could yield long-term profits. GSK settled a litigation concerning mRNA patent with BioNTech.BioNTech managed to double its Q2 Revenues because of increased COVID-19 vaccine sales. Other notable developments include a partnership with Bristol Myers for a bispecific cancer drug and a $1.2B purchase of CureVac, ending an mRNA patent dispute.
BIONTECH News Analytics from Sat, 28 Dec 2024 08:00:00 GMT to Fri, 31 Oct 2025 06:07:43 GMT - Rating 8 - Innovation 9 - Rumor 2
